Milnacipran and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Milnacipran
Apixaban
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You're taking Eliquis (apixaban), a blood thinner, along with Savella (milnacipran), a medicine for fibromyalgia. Both can make it a little easier to bleed. Apixaban blocks a clotting protein, and milnacipran (an SNRI) can affect the platelets that help your blood clot. Put together, they may raise your chance of bleeding or bruising.
This concern is theoretical, meaning it's based on how the drugs work rather than lots of reports, so try not to worry. The main thing is to watch for warning signs like unusual bruising, nosebleeds that won't stop, pink or red urine, black stools, or coughing up blood. If any happen, get help right away. Your care team can safely manage both medicines together.
Effect: Additive pharmacodynamic bleeding risk. Apixaban is a direct factor Xa inhibitor; SNRIs such as milnacipran impair serotonin-mediated platelet aggregation, giving additive effects on hemostasis. Neither is a prodrug; this is a PD, not PK, interaction.
- Direction/magnitude: Increased bleeding risk; magnitude not quantified.
- Onset: Unspecified; apixaban PD effect persists >=24 h after last dose.
- Evidence: Theoretical, but severity rated major.
Management: Continue both unless bleeding occurs. Counsel on blood-loss signs. Discontinue apixaban for active pathological hemorrhage; a specific anti-FXa reversal agent exists, and PCC/aPCC/rFVIIa may be considered. Clotting assays (PT/INR/aPTT, anti-FXa) are not useful to guide PCC use.
What happens
An increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Giving apixaban, a factor Xa inhibitor, together with other agents that influence hemostasis, for example a SNRI, can raise the likelihood of bleeding. Apixaban should be stopped when active pathological bleeding develops. A product that reverses the anti-factor Xa activity of apixaban is on the market. Apixaban's pharmacodynamic effect is anticipated to remain for a minimum of 24 hours following the last dose. Patients should be instructed about the signs and symptoms of blood loss and told to report these right away or present to an emergency room. In individuals with active pathological hemorrhage, apixaban should be discontinued. An agent capable of reversing apixaban's anti-factor Xa activity is available, and apixaban's pharmacodynamic effect can be expected to last for at least 24 hours after the final dose. Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are employed, it is not helpful and is not recommended to monitor apixaban's anticoagulation effect with a clotting test (PT, INR, or aPTT) or with anti-factor Xa (FXa) activity. Activated oral charcoal decreases the absorption of apixaban, which lowers apixaban plasma concentration1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
Keep taking both medicines as prescribed unless your prescriber tells you otherwise. The plan here is mostly about awareness and monitoring.
- Learn the signs of bleeding: easy bruising, nosebleeds, bleeding gums, pink or red urine, black or bloody stools, coughing or vomiting blood, or unusual weakness or dizziness.
- Report bleeding right away or go to an emergency room if it is serious.
- Tell any new doctor or dentist that you take both a blood thinner and an SNRI.
- Ask your pharmacist before adding aspirin, NSAIDs (like ibuprofen), or other blood thinners.
Rest assured, if bleeding ever occurs, hospitals have a reversal agent for apixaban.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Milnacipran and Apixaban together?
Taking milnacipran with apixaban can add to your bleeding risk, so watch closely for bruising or bleeding and report it promptly. Keep taking both as prescribed unless your care team advises otherwise. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Milnacipran and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Milnacipran and Apixaban interaction managed?
Keep taking both medicines as prescribed unless your prescriber tells you otherwise. The plan here is mostly about awareness and monitoring. Learn the signs of bleeding: easy bruising, nosebleeds, bleeding gums, pink or red urine, black or bloody stools, coughing or vomiting blood, or unusual weakness or dizziness. Report bleeding right away or go to an emergency room if it is serious. Tell any ne… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Milnacipran or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
Keep reading about Milnacipran
Keep reading about Apixaban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist